Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study |
| |
| Authors: | A Traboulsee A AL-Sabbagh R Bennett P Chang DKB Li the EVIDENCE Study Group the UBC MS/MRI Research Group |
| |
| Affiliation: | (1) Division of Neurology, Medicine, University of British Columbia, Vancouver, BC, Canada;(2) EMD Serono, Inc., Rockland, MA, USA;(3) Radiology, University of British Columbia, Vancouver, BC, Canada |
| |
| Abstract: | Background The EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study was an international, randomized, open-label, assessor-blinded, parallel-group study assessing the efficacy and tolerability of interferon (IFN) beta-1a, 44 mcg subcutaneously (sc) three times weekly (tiw), and IFN beta-1a, 30 mcg intramuscularly (im) once weekly (qw), in patients with relapsing-remitting multiple sclerosis (RRMS). The aim of this analysis was to assess whether reductions in T2 burden of disease (BOD) were greater for patients receiving IFN beta-1a, 44 mcg sc tiw, than for those treated with IFN beta-1a, 30 mcg im qw, and to assess the impact of neutralizing antibodies (NAbs). |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
